drugset / Trial / NCT04912765
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).
Timeline
- Start
- 2021-04-15
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neoantigen Dendritic Cell Vaccine | Vaccine | — | Other |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |